MYGN earnings date and last-quarter result: last quarter beat, P/E -1.31. Updated 2026-07-23.
Myriad Genetics (MYGN) Research Hub
Myriad Genetics (MYGN) trades on NASDAQ, US in the Healthcare (Medical - Diagnostics & Research) sector. As of 2026-10-26, shares last closed at 6.02 USD (+3.44%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.31, market cap 0.54B. This hub links to the full technical, earnings and options research available for MYGN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Diagnostics & Research) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.02 USD (+3.44%) |
| 52-week range | 2.81 USD – 6.43 USD |
| Trend regime | Range |
| 14-day RSI | 78.1 (Overbought) |
| Trailing P/E | -1.31 |
| Market cap | 0.54B |
| Dividend yield | 0.00% |
Available research for MYGN
Covered Call on MYGN: how it works, illustrative setup around the real 6.02 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MYGN: how it works, illustrative setup around the real 6.02 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MYGN: how it works, illustrative setup around the real 6.02 USD price, max profit/loss, breakeven and when to use it. Educational.
MYGN technical analysis: range, last 6.02 USD, RSI 78.1, 52w range 2.81 USD–6.43 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is MYGN in?
Myriad Genetics (MYGN) is classified under Healthcare (Medical - Diagnostics & Research), listed on NASDAQ, US.
Is MYGN in an uptrend or downtrend?
As of 2026-10-26, MYGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MYGN's trailing P/E ratio?
MYGN's trailing P/E is -1.31, with a market cap of 0.54B. See the earnings research page for full valuation detail.